Who are we

Biological medicines have revolutionized the treatment of many diseases.^1,2 However, their high cost places a significant burden on healthcare systems and can hinder patient access.^1,3

When the patent for a biological ‘reference’ medicine expires, a biosimilar follow-on medicine can be manufactured.^1,4 Biosimilars are more affordable than their reference biological medications, improving patient access and decreasing healthcare costs.¹

In Europe, use of biological medicines increased by as much as 100% following the introduction of biosimilars, leading to significant savings.³

Sandoz, a pioneer in the development of biosimilars, launched the world’s first biosimilar in 2006.⁵ Our biosimilars are now available in 100 countries and have 730+ million days of patient experience.⁵

Biosimilars follow a different, more detailed approval process compared to generic medicines.  To be approved in South Africa, a biosimilar must match the reference medicine in terms of safety, quality and efficacy, so doctors and patients can expect the same clinical outcome.⁶

Recent statistics confirm that, during 2020, $8 billion were saved in the United States of America (US) through the use of biosimilars. Their use is projected to save the US healthcare industry $133 billion by 2025.⁷

Sandoz is well placed to provide high-quality, affordable biosimilars to the South African market.